Navigation Links
Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint

DUBLIN, Ohio--(BUSINESS WIRE)--Jun 20, 2007 - Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced positive preliminary results from a multicenter Phase 2 clinical study of its lead clinical candidate, Lymphoseek(R) (Technetium Tc99m DTPA-mannosyl-dextran). Lymphoseek is a proprietary radioactive targeting agent being developed for use with handheld gamma detection devices, such as Neoprobe's neo2000(R) system, in a surgical procedure known as Sentinel Lymph Node Biopsy (SLNB). The primary endpoint of this multicenter, single-arm, open-label, within-patient, single-dose, multi-stage trial measured the rate at which Lymphoseek localized to lymphoid tissue with a goal of achieving 90% localization. In results reported today, localization of Lymphoseek to lymphoid tissue was observed in over 94% of the SLNB procedures performed as a part of the Phase 2 trial in patients with either breast cancer or melanoma.

This study is being conducted at five of the leading cancer centers in the U.S.: John Wayne Cancer Center; M.D. Anderson, the University of California, San Francisco; University Hospitals - Cleveland (Case Western Reserve); and the University of Louisville. Positive interim results from the trial were announced earlier this year. Neoprobe also reported that no drug-related significant adverse events have been noted in results analyzed to-date. Neoprobe now plans to begin winding down Phase 2 trial activities, collecting the required 30-day patient safety follow-up information and accumulating data to report to FDA. In parallel, Neoprobe is also preparing to submit its Phase 3 pivotal trial protocol to FDA.

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neo2000(R) line of gamma detection systems that are widely used by cancer surgeons and is commercializing the Quantix(R) line of blood flow measurement products developed by its subsidiary, Cardiosonix Ltd. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek(R) and RIGScan(R) CR. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com

Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company's products are forward-looking statements The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company's most recent Annual Report on Form 10-KSB and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

Contact

Neoprobe Corporation
Brent Larson, 614-793-7500 x133
Vice President/CFO
or
The Trout Group
Tim Ryan, 646-378-2924


'"/>




Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... January 19, 2017 Pfizer ... the Milner Therapeutics Consortium   Major ... Cambridge   The Milner ... PFE ) as a partner to the Milner Therapeutics ... enables the efficient transfer of materials between industry and ...
(Date:1/19/2017)... 18, 2017  ViewRay, Inc. (Nasdaq: ... only clinical MRI-guided radiation therapy system, announced today that ... $26.1 million through a private placement of its ... the financing and was joined by certain of ... Kearny Venture Partners, and an additional new institutional ...
(Date:1/19/2017)... Jan. 18, 2017 The Academy of ... Drug Administration (FDA) for its release today of ... health decision makers can proactively share clinical and ... well as emerging therapies awaiting FDA approval. ... recommendations that AMCP developed during two multi-stakeholder meetings ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... Wells Pharmacy ... enhancement of their 503A compounding pharmacy located in Ocala, Florida. , Meeting ... and patients throughout the United States for high-quality human anti-aging and wellness ...
(Date:1/19/2017)... , ... January 19, 2017 , ... WhoHaha , ... up with the American Heart Association (AHA) to produce a three-part video series that ... will debut as part of the launch of AHA’s Healthy For Good™ movement, which ...
(Date:1/19/2017)... Somerset, N.J. (PRWEB) , ... January 19, 2017 ... ... advanced delivery technologies and development solutions for drugs, biologics and consumer health products, ... Medicines with Lipids,” with Gattefossé, the leader in innovative excipients and drug delivery ...
(Date:1/19/2017)... ... January 19, 2017 , ... In 2009, ... fillers that resulted in severe facial disfiguration. After four frightening years of isolation ... at UCLA Medical Center, who removed the substances in a partial facial transplant ...
(Date:1/19/2017)... ... January 19, 2017 , ... Ultimate Medical Academy (UMA) ... are passionate about making a difference in the lives of the next generation ... a nonprofit healthcare educational institution, has more than 30,000 alumni and employs more ...
Breaking Medicine News(10 mins):